Scientific Publications & Presentations
|Publications | Presentations|
|Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma|
Authors: Nosov D, Esteves B, Lipatov O, Lyulko A, Anischenko A, Chacko R, Doval D, Strahs A, Slichenmyer W, and Bhargava P JCO May 10, 2012:1678-1685; DOI:10.1200/JCO.2011.35.3524. Click here for link to article.
|Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors.|
Authors: Eskens FALM, de Jonge MJA, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J.
Clin Cancer Res. 10.1158/1078-0432.CCR-11-0411. (October 5, 2011). Click here for link to article.
|Development of second-generation VEGFR tyrosine kinase inhibitors: Current status|
Authors: Bhargava P, Robinson MO.
Curr Oncol Rep. 2011. doi:10.1007/s11912-011-0154-3. Click here for link to article.
|GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling|
Authors: Bai A, Meetze K, Vo NY, Kollipara S, Mazsa EK, Winston WM, Weiler S, Poling LL, Chen T, Ismail NS, Jiang J, Lerner L, Gyuris J, Weng Z.
Cancer Res. 2010 Oct 1;70(19):7630-9. Epub 2010 Aug 13. Click here for link to article.
|Non-germline genetically engineered mouse models for translational cancer research|
Authors: Joerg Heyer, Lawrence N. Kwong, Scott W. Lowe and Lynda Chin
Nature Reviews Cancer, July 2010, vol. 10, no. 7, 470-80. Click here for article.
|Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.|
Authors: Yinghui Zhou, William M. Rideout 3rd, Tong Zi, Angela Bressel, Shialaja Reddypalli, Rebecca Rancourt, Jin K. Woo, James W. Horner, Lynda Chin, M. Isabel Chiu, Marcus Bosenberg, Tyler Jacks, Steven C. Clark, Ronald A. Depinho, Murray O. Robinson, and Joerg Heyer.
Nat Biotechnol. 2010 Jan;28(1):71-8. Epub 2009 Dec 20
|Human-in-mouse breast cancer model|
Authors: Min Wu and Murray O. Robinson
Cell Cycle 2009, vol. 8, 2317-18. Click here for article.
|Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice|
Authors: Min Wu, Lina Jung, Adrian B. Coopers, Christina Fleet, Lihao Chen, Lyne Breault, Kimberly Clark, Zhuau Cai, Sylvie Vincent, Steve Bottega, Qiong Shen, Andrea Richardson, Marcus Bosenburg, Stephen P. Naber, Ronald A. DePinho, Charlotte Kuperwasser, and Murray O. Robinson
Proc Natl Acad Sci U S A. 2009, vol.106, 7022-27. Click here for article.
|Cancer Drug Discovery and Development: The Oncogenomics Handbook|
Edited by W. J. LaRochelle and R. A. Shimkets © Humana Press Inc., April 2005.
|Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Development (Chapter 16)|
Authors: Ronan C. O'Hagan, Min Wu, William M. Rideout III, Yinghui Zhou and Joerg Heyer
|Essential role for oncogenic Ras in tumour maintenance|
Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA.
Nature. 1999 Jul 29; 400(6743): 468-72.